SG11201901548SA - Anti-tim-3 antibodies and use thereof - Google Patents

Anti-tim-3 antibodies and use thereof

Info

Publication number
SG11201901548SA
SG11201901548SA SG11201901548SA SG11201901548SA SG11201901548SA SG 11201901548S A SG11201901548S A SG 11201901548SA SG 11201901548S A SG11201901548S A SG 11201901548SA SG 11201901548S A SG11201901548S A SG 11201901548SA SG 11201901548S A SG11201901548S A SG 11201901548SA
Authority
SG
Singapore
Prior art keywords
science park
beijing
changping
international
tim
Prior art date
Application number
SG11201901548SA
Inventor
Liu Xue
Qi Liu
Tong Zhang
Hao Peng
Min Wei
Kang Li
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of SG11201901548SA publication Critical patent/SG11201901548SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) W I PO I PCT 0111111010 0111 °nolo III 011101110111 O II oimIE (10) International Publication Number WO 2018/036561 Al (51) International Patent Classification: CO7K 16/28 (2006.01) A61P 35/00 (2006.01) A61K 39/395 (2006.01) A61P 37/00 (2006.01) (21) International Application Number: PCT/CN2017/099098 (22) International Filing Date: 25 August 2017 (25.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2016/096924 26 August 2016 (26.08.2016) CN (71) Applicant: BEIGENE, LTD.; c/o Mourant Ozannes Cor- porate Services (Cayman) Limited, 94 Solaris Avenue, Ca- mana Bay, Grand Cayman KY1-1108 (KY). (72) Inventor; and (71) Applicant (for SC only): ZHANG, Tong [CN/CN]; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). (72) Inventors: XUE, Liu; No.30 Science Park Road, Zhong- guancun Life Science Park, Changping, Beijing 102206 (CN). LIU, Qi; No.30 Science Park Road, Zhongguan- cun Life Science Park, Changping, Beijing 102206 (CN). PENG, Hao; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). WEI, Min; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). LI, Kang; No.30 Science Park Road, Zhongguancun Life Science Park, Changping, Beijing 102206 (CN). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) = (74) Agent: WU, FENG & ZHANG CO.; Room 305, Tower B, Beijing Aerospace Cpmiec Building, Beijing 100080 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ANTI-TIM-3 ANTIBODIES AND USE THEREOF 0 (57) : Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The \" anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders 0 that may be modulated by Tim-3-mediated functions.
SG11201901548SA 2016-08-26 2017-08-25 Anti-tim-3 antibodies and use thereof SG11201901548SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016096924 2016-08-26
PCT/CN2017/099098 WO2018036561A1 (en) 2016-08-26 2017-08-25 Anti-tim-3 antibodies and use thereof

Publications (1)

Publication Number Publication Date
SG11201901548SA true SG11201901548SA (en) 2019-03-28

Family

ID=61246369

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901548SA SG11201901548SA (en) 2016-08-26 2017-08-25 Anti-tim-3 antibodies and use thereof
SG10201912199XA SG10201912199XA (en) 2016-08-26 2017-08-25 Anti-tim-3 antibodies and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912199XA SG10201912199XA (en) 2016-08-26 2017-08-25 Anti-tim-3 antibodies and use thereof

Country Status (15)

Country Link
US (3) US11203637B2 (en)
EP (2) EP3504243A4 (en)
JP (2) JP6968872B2 (en)
KR (1) KR102460525B1 (en)
CN (3) CN116655790A (en)
AU (1) AU2017317227A1 (en)
BR (1) BR112019003976A2 (en)
CA (1) CA3034962A1 (en)
EA (1) EA201990594A1 (en)
MX (1) MX2019002242A (en)
NZ (1) NZ751246A (en)
SG (2) SG11201901548SA (en)
TW (2) TW202246347A (en)
WO (1) WO2018036561A1 (en)
ZA (1) ZA201901113B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112457403B (en) * 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 anti-PD 1 antibodies and their use as therapeutic and diagnostic agents
CN106604742B (en) 2014-07-03 2019-01-11 百济神州有限公司 Anti- PD-L1 antibody and its purposes as therapeutic agent and diagnosticum
JP6993056B2 (en) 2016-07-05 2022-02-15 ベイジーン リミテッド Combination of PD-1 antagonist and RAF inhibitor for cancer treatment
TWI780057B (en) 2016-07-14 2022-10-11 美商必治妥美雅史谷比公司 Antibodies against tim3 and uses thereof
CN110087680B (en) 2016-08-19 2024-03-19 百济神州有限公司 Treatment of cancer using combination products comprising BTK inhibitors
EP3504243A4 (en) 2016-08-26 2020-03-11 BeiGene, Ltd. Anti-tim-3 antibodies and use thereof
JP2019537438A (en) 2016-11-01 2019-12-26 アナプティスバイオ インコーポレイティッド Antibodies to TIM-3 (T cell immunoglobulin and mucin protein 3)
MA47206A (en) 2017-01-09 2019-11-13 Tesaro Inc CANCER TREATMENT METHODS USING ANTI-TIM-3 ANTIBODIES
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. Immunotherapy for hepatocellular carcinoma
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
CN111801334B (en) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors
EP3768725A4 (en) * 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited Novel anti-tim-3 antibodies
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
CN116789827A (en) * 2018-04-12 2023-09-22 南京维立志博生物科技有限公司 Methods of treating diseases using TIM-3 binding antibodies
EP3842071A4 (en) * 2018-08-20 2022-05-25 Jiangsu Hengrui Medicine Co., Ltd. Use of tim-3 antibody in preparation of medicines for treating tumors
MX2020013428A (en) * 2018-08-21 2021-07-16 Albert Einstein College Of Medicine Monoclonal antibodies against human tim-3.
CN114174537A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Cell localization features and combination therapies
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
EP3986462A4 (en) * 2019-06-21 2023-07-19 Single Cell Technology, Inc. Anti-tim-3 antibodies
CN110498855A (en) * 2019-07-25 2019-11-26 钟小泉 A kind of TIM-3 antibody and application thereof
EP4061845A4 (en) * 2019-11-21 2023-12-13 BeiGene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
CN114507284B (en) * 2020-05-09 2023-05-26 华博生物医药技术（上海）有限公司 Antibodies against TIGIT, methods of preparation and uses thereof
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
CN112940127A (en) * 2021-03-12 2021-06-11 北京广未生物科技有限公司 Application of bone marrow mesenchymal stem cells in combination with monoclonal antibody in treatment of cancer
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022223048A1 (en) * 2021-04-23 2022-10-27 Suzhou Neologics Bioscience Co. , Ltd. Tim-3-targetting antibodies and uses thereof
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024041652A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment
WO2024044675A1 (en) 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
WO2024041651A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP1406653A4 (en) * 2001-06-29 2005-05-04 Univ Leland Stanford Junior T cell regulatory genes and methods of use thereof
EP3020413A1 (en) * 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
JP2011500730A (en) 2007-10-26 2011-01-06 ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント Treatment and diagnostic method using Tim-3
EP2303926A1 (en) 2008-06-20 2011-04-06 Oklahoma Medical Research Foundation Immunogenic memapsin 2 -secretase peptides and methods of use
TWI629483B (en) 2010-06-11 2018-07-11 協和醱酵麒麟有限公司 anti-TIM-3 antibody
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN102492038B (en) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof
WO2015031541A1 (en) * 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
CN112457403B (en) 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 anti-PD 1 antibodies and their use as therapeutic and diagnostic agents
CN103721255A (en) * 2014-01-07 2014-04-16 苏州大学 Application of co-blocking of PD-1 and TIM-3 signal paths to anti-stomach-cancer treatment
JOP20200096A1 (en) * 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CN106604742B (en) * 2014-07-03 2019-01-11 百济神州有限公司 Anti- PD-L1 antibody and its purposes as therapeutic agent and diagnosticum
CA2965960A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
PT3215532T (en) * 2014-11-06 2019-12-18 Hoffmann La Roche Anti-tim3 antibodies and methods of use
EP3504243A4 (en) 2016-08-26 2020-03-11 BeiGene, Ltd. Anti-tim-3 antibodies and use thereof

Also Published As

Publication number Publication date
BR112019003976A2 (en) 2019-05-28
EP3970749A1 (en) 2022-03-23
CA3034962A1 (en) 2018-03-01
US20220135675A1 (en) 2022-05-05
JP6968872B2 (en) 2021-11-17
JP2022027659A (en) 2022-02-10
TW202246347A (en) 2022-12-01
KR20190042037A (en) 2019-04-23
JP2019529373A (en) 2019-10-17
ZA201901113B (en) 2020-10-28
SG10201912199XA (en) 2020-02-27
JP7158552B2 (en) 2022-10-21
CN116655790A (en) 2023-08-29
US20240076375A1 (en) 2024-03-07
KR102460525B1 (en) 2022-11-01
EA201990594A1 (en) 2019-08-30
EP3504243A4 (en) 2020-03-11
US11203637B2 (en) 2021-12-21
MX2019002242A (en) 2019-08-16
CN109790218B (en) 2023-03-03
CN116478290A (en) 2023-07-25
AU2017317227A1 (en) 2019-04-11
CN109790218A (en) 2019-05-21
US20190276533A1 (en) 2019-09-12
EP3504243A1 (en) 2019-07-03
WO2018036561A1 (en) 2018-03-01
NZ751246A (en) 2023-04-28
TW201819414A (en) 2018-06-01
TWI769174B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201901716TA (en) Adenovirus armed with bispecific t cell engager (bite)
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201901351UA (en) A patient interface, system and method
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201901347UA (en) Compositions and methods for cancer immunotherapy
SG11201808829VA (en) Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201805755SA (en) Methods of administering hepcidin
SG11201908275XA (en) Peptides and methods for the treatment of diabetes
SG11201810801QA (en) Brain delivery protein